These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 11386316)

  • 1. Angiotensin-II-receptor inhibitors in pregnancy.
    Chung NA; Lip GY; Beevers M; Beevers DG
    Lancet; 2001 May; 357(9268):1620-1. PubMed ID: 11386316
    [No Abstract]   [Full Text] [Related]  

  • 2. Valsartan. Just a second-line antihypertensive drug.
    Can Fam Physician; 1999 Nov; 45():2626-8, 2630-3. PubMed ID: 10587770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiotensin receptor blockers and myocardial infarction: the importance of dosage.
    Sarzani R; Dessì-Fulgheri P
    J Hypertens; 2006 Aug; 24(8):1679-81; author reply 1681-2. PubMed ID: 16877973
    [No Abstract]   [Full Text] [Related]  

  • 4. Fetal toxic effects and angiotensin-II-receptor antagonists.
    Martinovic J; Benachi A; Laurent N; Daikha-Dahmane F; Gubler MC
    Lancet; 2001 Jul; 358(9277):241-2. PubMed ID: 11480433
    [No Abstract]   [Full Text] [Related]  

  • 5. [When after myocardial infarction a pump weakness remains. ACE inhibitors and AT-1 blockers equivalent].
    MMW Fortschr Med; 2003 Dec; 145(49):18-9. PubMed ID: 14963986
    [No Abstract]   [Full Text] [Related]  

  • 6. Angiotensin-II-receptor inhibitors in pregnancy.
    Hinsberger A; Wingen AM; Hoyer PF
    Lancet; 2001 May; 357(9268):1620. PubMed ID: 11386315
    [No Abstract]   [Full Text] [Related]  

  • 7. [Fetal toxicity of angiotensin-II-receptor inhibitors. Case report].
    Roger N; Popovic I; Madelenat P; Mahieu-Caputo D
    Gynecol Obstet Fertil; 2007 Jun; 35(6):556-60. PubMed ID: 17544313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure: impact on the early morning period.
    White WB; Lacourciere Y; Davidai G
    Am J Hypertens; 2004 Apr; 17(4):347-53. PubMed ID: 15062889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Course and outcome of pregnancy after maternal exposure to angiotensin-II-receptor blockers--case report and review of the literature.
    Enzensberger C; Eskef K; Schwarze A; Faas D; Axt-Fliedner R
    Ultraschall Med; 2012 Oct; 33(5):493-6. PubMed ID: 21630188
    [No Abstract]   [Full Text] [Related]  

  • 10. Pregnancy outcome after in utero exposure to angiotensin converting enzyme inhibitors or angiotensin receptor blockers.
    Diav-Citrin O; Shechtman S; Halberstadt Y; Finkel-Pekarsky V; Wajnberg R; Arnon J; Di Gianantonio E; Clementi M; Ornoy A
    Reprod Toxicol; 2011 May; 31(4):540-5. PubMed ID: 21338666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [First fixed combination of sartan and high-dosage diuretic. A strong duo against high blood pressure].
    MMW Fortschr Med; 2004 Apr; 146(14):45. PubMed ID: 15344757
    [No Abstract]   [Full Text] [Related]  

  • 12. [New effective dosage of valsartan. High dosage--effective against high blood pressure].
    MMW Fortschr Med; 2007 Nov; 149(46):52-3. PubMed ID: 18069195
    [No Abstract]   [Full Text] [Related]  

  • 13. [Therapy of heart failure. 2 neurohormone blockers are enough].
    MMW Fortschr Med; 2002 Sep; 144(35-36):57. PubMed ID: 12380364
    [No Abstract]   [Full Text] [Related]  

  • 14. [Hypertension, obesity, erectile dysfunction. What kind of drug to choose].
    Maksimov ML; Ermolaeva AS; Dralova OV
    Kardiologiia; 2011; 51(7):58-64. PubMed ID: 21878087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of valsartan added to background ACE inhibitor therapy in patients with heart failure: results from Val-HeFT.
    Krum H; Carson P; Farsang C; Maggioni AP; Glazer RD; Aknay N; Chiang YT; Cohn JN
    Eur J Heart Fail; 2004 Dec; 6(7):937-45. PubMed ID: 15556056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exforge HCT.
    Med Lett Drugs Ther; 2009 Jun; 51(1314):47. PubMed ID: 19528888
    [No Abstract]   [Full Text] [Related]  

  • 17. Aldosterone breakthrough during aliskiren, valsartan, and combination (aliskiren + valsartan) therapy.
    Bomback AS; Rekhtman Y; Klemmer PJ; Canetta PA; Radhakrishnan J; Appel GB
    J Am Soc Hypertens; 2012; 6(5):338-45. PubMed ID: 22995802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiotensin II receptor blocker-induced angioedema in the oral floor and epiglottis.
    Shino M; Takahashi K; Murata T; Iida H; Yasuoka Y; Furuya N
    Am J Otolaryngol; 2011; 32(6):624-6. PubMed ID: 21324549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiotensin receptor blockers and myocardial infarction.
    Verma S; Strauss M
    BMJ; 2004 Nov; 329(7477):1248-9. PubMed ID: 15564232
    [No Abstract]   [Full Text] [Related]  

  • 20. Vildagliptin, a novel dipeptidyl peptidase IV inhibitor, has no pharmacokinetic interactions with the antihypertensive agents amlodipine, valsartan, and ramipril in healthy subjects.
    He YL; Ligueros-Saylan M; Sunkara G; Sabo R; Zhao C; Wang Y; Campestrini J; Pommier F; Dole K; Marion A; Dole WP; Howard D
    J Clin Pharmacol; 2008 Jan; 48(1):85-95. PubMed ID: 17986525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.